Grants per year
Personal profile
Training Experience
| 2003 | Residency, Royal College of Physicians, Ireland |
| 2009 | Fellowship, University of Texas Health Science Center, San Antonio |
| 2009 | Fellowship, Royal College of Physicians, Ireland |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Cancer Research, National University of Ireland
… → 2009
MBBChBAO, Medicine, National University of Ireland
… → 2000
Fingerprint
Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #MK-6482-015: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VH
Mahalingam, D. (PD/PI)
4/7/25 → 4/7/28
Project: Research project
-
Prot #CF33-CD19-101: A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumor
Mahalingam, D. (PD/PI)
Medpace Clinical Research LLC, Imugene Limited
8/9/24 → 8/9/27
Project: Research project
-
Prot #CP-MVC-101-01: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic
Mahalingam, D. (PD/PI)
PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.
4/22/24 → 4/22/27
Project: Research project
-
Prot #2138-CL-0101: A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Exp
Mahalingam, D. (PD/PI)
ICON Clinical Research, LLC, Astellas Pharma Global Development, Inc.
4/15/24 → 4/15/27
Project: Research project
-
Prot #M24-427: A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Mahalingam, D. (PD/PI)
3/13/24 → 3/13/27
Project: Research project
-
A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers
Mahalingam, D., Owonikoko, T. K., Delpassand, E., Mulcahy, M. F., Kalyan, A., Ulahannan, S., Cheung, K., Izumi, Y., Johansen, M., Madden, T., Shimoyama, S., Subach, R. A., Suzuki, T., Wages, D. S., Wheeler, C. & Richardson, D. L., Jan 1 2025, In: cancer. 131, 1, e35680.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer
Gennaro, N., Soliman, M., Borhani, A. A., Kelahan, L., Savas, H., Avery, R. J., Subedi, K., Trabzonlu, T. A., Krumpelman, C., Yaghmai, V., Chae, Y. K., Lorch, J., Mahalingam, D., Mulcahy, M., Benson III, A. B., Bagci, U. & Velichko, Y. S., Mar 2025, In: Tomography. 11, 3, 20.Research output: Contribution to journal › Article › peer-review
Open Access -
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial
Goldman, J. W., Bueno, A. M., Dooms, C., Jhaveri, K., de Miguel, M., Piha-Paul, S. A., Unni, N., Zick, A., Mahipal, A., Suga, J. M., Naltet, C., Antoñanzas, M., Crown, J., Bebchuk, J., Eli, L. D., Lowenthal, B. H. & Mahalingam, D., May 2025, In: Clinical Lung Cancer. 26, 3, p. 191-200.e1Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors
Chae, Y. K., Duan, R., Chung, L. I. Y., Oh, Y., Alexiev, B., Shin, S., Kim, S., Helenowski, I., Matsangou, M., Villaflor, V. M. & Mahalingam, D., Apr 2025, In: Cancer medicine. 14, 7, e70724.Research output: Contribution to journal › Article › peer-review
Open Access -
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir, T., Moloney, C. & Mahalingam, D., Mar 2025, In: Cancers. 17, 5, 715.Research output: Contribution to journal › Review article › peer-review
Open Access
Datasets
-
Data for: Case Report of Prostate Ductal Adenocarcinoma Presenting with Hematuria
Pawlowski, J. (Contributor), Mahalingam, D. (Contributor) & Ha, C. S. (Contributor), Mendeley Data, May 18 2018
DOI: 10.17632/3kkg7vntxc.1, https://data.mendeley.com/datasets/3kkg7vntxc
Dataset